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Introduction
Levetiracetam is a novel antiepileptic used for treatment of partial and generalized epilepsy. 
Its mechanism of action is unclear though it is thought to bind to a presynaptic vesicle 
protein that ultimately reduces the synaptic release of glutamate, impeding conduction of 
epileptic action potentials across the synapse.1 Levetiracetam is frequently used due to its 
ease of oral administration, excellent bioavailability and low rate of drug interactions as it is 
not metabolized by the liver or bound significantly to serum proteins.2, 3 Adverse cognitive 
effects are atypical; however, central nervous system adverse effects are relatively common, 
with behavioral symptoms occurring in up to 16% of patients in randomized controlled 
trials.4 Frequently reported behavioral symptoms include depression, hostility, agitation, 
emotional lability, anger, nervousness, and depersonalization. Non-behavioral central 
nervous system effects include sedation, headache, and asthenia.5 Psychosis is infrequently 
associated with levetiracetam, occurring in approximately 1% of patients, but well described 
in multiple case reports.6, 7 Researchers have explored the use of levetiracetam as a mood 
stabilizer for treatment of both depressive and manic phases of bipolar disorder with mixed 
results.8–10 Despite the known association between levetiracetam and aggression and 
irritability, there are no reported cases in the literature of levetiracetam precipitating manic 
symptoms. In the case we report, we describe the acute onset of mania following 
levetiracetam therapy in a woman with no prior history of mania or hypomania.
Case report
Ms. B was a 58-year-old woman with stage IV inflammatory breast cancer and a remote 
history of postpartum depression who was admitted to the cancer hospital for evaluation of 
brief stuttering spells. Upon admission to the hospital, her vital signs were unremarkable 
with the exception of tachycardia (pulse 120). She did not exhibit any abnormal movements 
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or tremor and she was no longer experiencing stuttering spells. A comprehensive neurologic 
assessment, including neurology consultation, brain MRI with and without contrast, 
laboratory work-up and video electroencephalogram did not reveal any explanatory etiology 
for her symptoms. Her hospital course was unremarkable and she was discharged home with 
a new prescription for levetiracetam 750mg twice daily as prophylaxis for possible seizures. 
She did not receive any doses of steroids, antihistamines, or antidepressants during her 
hospital stay. Two weeks prior, she had received oral dexamethasone as an anti-emetic 
without incident. She continued to take lorazepam 1mg at night as previously prescribed. 
She was originally provided this medication three months earlier for chemotherapy-
associated nausea.
Two weeks later, she presented to the outpatient oncology clinic with symptoms of acute 
mania. During the previous one and a half weeks, she reported racing thoughts, erratic and 
impulsive behavior, decreased need for sleep (requiring less than 3 hours of sleep per night), 
and emotional lability with irritability. She was paranoid and had called the police to her 
home due to her belief that her son was trying to harm her and wanted her dead. She was 
verbally aggressive with strangers and was escorted from local stores by security. She gave 
away all of her available spending money to strangers. Upon examination, her speech was 
rapid and hyper-verbal. Her affect was expansive and she described her mood as “great.” She 
was restless and unable to sit for longer than a few minutes. Her thought process was 
tangential with loosened associations. She denied suicidality, homicidality or abnormal 
perceptions, though she continued to express paranoia toward her son and desire to pursue 
large purchases such as a vacation home. She denied any misuse of alcohol or illicit 
substances during this period. Drugs of abuse were not tested though Ms. B had no previous 
history of substance misuse.
Ms. B and her adult son indicated that she had discontinued the levetiracetam three days 
prior to her evaluation due to concern that it precipitated her symptoms. Both the patient and 
her son confirmed that she had no prior history of mania or hypomania prior to starting 
levetiracetam therapy. There was no known family history of bipolar illness.
Due to the severity of her symptoms, her levetiracetam was held and scheduled daytime 
lorazepam 1mg daily and olanzapine 5mg at night were added to her medication regimen. 
She continued her previously prescribed nighttime lorazepam and no additional medications 
were used for management of insomnia. Within two weeks, her behavior had improved and 
she resumed her scheduled chemotherapy. During the following month, her olanzapine was 
discontinued and lorazepam tapered to her previous dosage without incident. She was 
periodically followed by the psycho-oncology service for six subsequent months and no 
further episodes of mania or hypomania were noted.
Discussion
Levetiracetam is an antiepileptic with known neuropsychiatric adverse effects. To our 
knowledge, this is the first known report of levetiracetam-induced mania. While the 
mechanism of this adverse effect remains unknown, the temporal relationship between 
emergence and subsequent resolution of symptoms with initiation and cessation of treatment 
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with her antiepileptic medication is compelling. Notably, she was not treated with 
concomitant medications like steroids that can precipitate symptoms of mania and it appears 
unlikely that her psychiatric symptoms were due to primary seizure etiology given the 
negative neurologic work-up.
In general, psychiatric disorders in patients with epilepsy are common and multifactorial in 
origin. Patients with history of psychiatric disorders may demonstrate an increased 
susceptibility to the behavioral adverse effects of antiepileptics suggesting an underlying 
vulnerability to antiepileptic central nervous system toxicity.4, 11 However, the development 
of manic symptoms with antiepileptic treatment is unusual. Many, if not most, antiepileptic 
medications are also used for their mood-stabilizing properties. There are several reports that 
have specifically used levetiracetam for treatment of mania.12, 13 Levetiracetam, though, is 
an antiepileptic with unique mechanism of action and known association with aggression, 
hostility, and psychosis. The cause of these behavioral effects with levetiracetam remains 
unknown.
In one prospective study of 553 patients treated with levetiracetam, behavioral abnormalities 
were the most frequently cited reason for premature medication discontinuation.14 Known 
risk factors for the development of behavioral disturbance with levetiracetam include rapid 
dosage titration, having a learning disability, prior psychiatric history or symptomatic 
generalized epilepsy.14 Other studies on the relationship between dosage and risk of 
aggression with levetiracetam are conflicting.15 In the case we have presented, the rapid 
dosage escalation of levetiracetam as well as her previous psychiatric history may have 
contributed to her symptomatology.
More research is needed on the mechanisms of behavioral disorders with levetiracetam as 
well as more specific predictors of which patient populations are most susceptible to these 
symptoms. Prospective studies of levetiracetam that use formal psychiatric assessments and 
measurement of irritability and aggression would help with elucidating this complex 
relationship. It is possible that these two symptoms may be reflective of an underlying 
hypomania, mixed mania, or acute mania in patients who develop levetiracetam associated 
adverse effects.
Given the increasingly widespread use of this newer anti-epileptic,16, 17 clinicians should 
consider close monitoring of patients for treatment-emergent mood and psychotic 
symptoms, including the possibility of mania. In addition, slower titration rates of 
levetiracetam, particularly in patients with previous psychiatric histories, should be 
considered.
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